Melanoma Proteomics Unveiled : Harmonizing Diverse Data Sets for Biomarker Discovery and Clinical Insights via MEL-PLOT
(2025) In Journal of Proteome Research 24(6). p.3117-3128- Abstract
Using several melanoma proteomics data sets we created a single analysis platform that enables the discovery, knowledge build, and validation of diagnostic, predictive, and prognostic biomarkers at the protein level. Quantitative mass-spectrometry-based proteomic data was obtained from five independent cohorts, including 489 tissue samples from 394 patients with accompanying clinical metadata. We established an interactive R-based web platform that enables the comparison of protein levels across diverse cohorts, and supports correlation analysis between proteins and clinical metadata including survival outcomes. By comparing differential protein levels between metastatic, primary tumor, and nonmalignant samples in two of the cohorts, we... (More)
Using several melanoma proteomics data sets we created a single analysis platform that enables the discovery, knowledge build, and validation of diagnostic, predictive, and prognostic biomarkers at the protein level. Quantitative mass-spectrometry-based proteomic data was obtained from five independent cohorts, including 489 tissue samples from 394 patients with accompanying clinical metadata. We established an interactive R-based web platform that enables the comparison of protein levels across diverse cohorts, and supports correlation analysis between proteins and clinical metadata including survival outcomes. By comparing differential protein levels between metastatic, primary tumor, and nonmalignant samples in two of the cohorts, we identified 274 proteins showing significant differences among the sample types. Further analysis of these 274 proteins in lymph node metastatic samples from a third cohort revealed that 45 proteins exhibited a significant effect on patient survival. The three most significant proteins were HP (HR = 4.67, p = 2.8e-06), LGALS7 (HR = 3.83, p = 2.9e-05), and UBQLN1 (HR = 3.2, p = 4.8e-05). The user-friendly interactive web platform, accessible at https://www.tnmplot.com/melanoma, provides an interactive interface for the analysis of proteomic and clinical data. The MEL-PLOT platform, through its interactive capabilities, streamlines the creation of a comprehensive knowledge base, empowering hypothesis formulation and diligent monitoring of the most recent advancements in the domains of biomedical research and drug development.
(Less)
- author
- organization
-
- Mass Spectrometry
- Clinical Chemistry, Malmö (research group)
- Clinical Protein Science and Imaging (research group)
- LUCC: Lund University Cancer Centre
- Division for Biomedical Engineering
- Medical oncology
- LU Profile Area: Light and Materials
- Department of Translational Medicine
- EpiHealth: Epidemiology for Health
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- mass spectrometry, proteomics, skin cancer, survival, tumor progression
- in
- Journal of Proteome Research
- volume
- 24
- issue
- 6
- pages
- 12 pages
- publisher
- The American Chemical Society (ACS)
- external identifiers
-
- scopus:105004395993
- pmid:40322912
- ISSN
- 1535-3893
- DOI
- 10.1021/acs.jproteome.4c00749
- language
- English
- LU publication?
- yes
- id
- 8404ad9e-e55e-441f-868a-a04cd26f8826
- date added to LUP
- 2025-09-24 11:23:17
- date last changed
- 2025-09-25 03:20:26
@article{8404ad9e-e55e-441f-868a-a04cd26f8826, abstract = {{<p>Using several melanoma proteomics data sets we created a single analysis platform that enables the discovery, knowledge build, and validation of diagnostic, predictive, and prognostic biomarkers at the protein level. Quantitative mass-spectrometry-based proteomic data was obtained from five independent cohorts, including 489 tissue samples from 394 patients with accompanying clinical metadata. We established an interactive R-based web platform that enables the comparison of protein levels across diverse cohorts, and supports correlation analysis between proteins and clinical metadata including survival outcomes. By comparing differential protein levels between metastatic, primary tumor, and nonmalignant samples in two of the cohorts, we identified 274 proteins showing significant differences among the sample types. Further analysis of these 274 proteins in lymph node metastatic samples from a third cohort revealed that 45 proteins exhibited a significant effect on patient survival. The three most significant proteins were HP (HR = 4.67, p = 2.8e-06), LGALS7 (HR = 3.83, p = 2.9e-05), and UBQLN1 (HR = 3.2, p = 4.8e-05). The user-friendly interactive web platform, accessible at https://www.tnmplot.com/melanoma, provides an interactive interface for the analysis of proteomic and clinical data. The MEL-PLOT platform, through its interactive capabilities, streamlines the creation of a comprehensive knowledge base, empowering hypothesis formulation and diligent monitoring of the most recent advancements in the domains of biomedical research and drug development.</p>}}, author = {{Bartha, Áron and Weltz, Boglárka and Betancourt, Lazaro Hiram and Gil, Jeovanis and Pinto de Almeida, Natália and Bianchini, Giampaolo and Szeitz, Beáta and Szadai, Leticia and Pla, Indira and Kemény, Lajos V. and Jánosi, Ágnes Judit and Hong, Runyu and Rajeh, Ahmad and Nogueira, Fábio and Doma, Viktória and Woldmar, Nicole and Guedes, Jéssica and Újfaludi, Zsuzsanna and Kim, Yonghyo and Szarvas, Tibor and Pahi, Zoltan and Pankotai, Tibor and Szasz, A. Marcell and Sanchez, Aniel and Baldetorp, Bo and Tímár, József and Németh, István Balázs and Kárpáti, Sarolta and Appelqvist, Roger and Domont, Gilberto Barbosa and Pawlowski, Krzysztof and Wieslander, Elisabet and Malm, Johan and Fenyo, David and Horvatovich, Peter and Marko-Varga, György and Győrffy, Balázs}}, issn = {{1535-3893}}, keywords = {{mass spectrometry; proteomics; skin cancer; survival; tumor progression}}, language = {{eng}}, number = {{6}}, pages = {{3117--3128}}, publisher = {{The American Chemical Society (ACS)}}, series = {{Journal of Proteome Research}}, title = {{Melanoma Proteomics Unveiled : Harmonizing Diverse Data Sets for Biomarker Discovery and Clinical Insights via MEL-PLOT}}, url = {{http://dx.doi.org/10.1021/acs.jproteome.4c00749}}, doi = {{10.1021/acs.jproteome.4c00749}}, volume = {{24}}, year = {{2025}}, }